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High-Dose Interleukin-2 Administration in the Oncology Medical-Surgical Setting -

An Innovation to Impact Cost Efficiencies, Clinical Outcomes and the Ideal Patient Experience
7C Hematology/Oncology Unit Staff Members

Lehigh Valley Health Network, Allentown, PA

Objective

Treatment Plan

Discuss program components for successful administration of
high-dose IL-2 outside the traditional step-down or critical care
setting, in a 20-bed medical-surgical hematology/oncology unit.  

1 Course
Cycle #1 – IL-2 Q 8 hours
X maximum 14 doses

Evidence and Background
IL-2
• Biotherapy that stimulates immune reaction
• Durable and complete responses in metastatic melanoma &
renal cell carcinoma  
Routine Administration
• Step-down or critical care unit
• No published reports in medical-surgical setting  

IL-2 Assessment Criteria
System
Cardiac

Relative Criteria
ST 120-130
Frequent PVCs

Dermatologic.
GI

Immune

Diarrhea
>1000cc/shift
Abdominal
distention

Guiac +Stools,
sputum or emesis
Platelets. <50,000

Neurologic
Pulmonary

Goal
• Administer a maximum of  14 IL-2 doses
Staffing
• 2 patients to 1 nurse
Consistent Timed Therapy - q 8 hours
• 3:00 pm; 11:00 pm; 7:00 am
Managed Solely by Attending Physician
• No residents or fellows
Routine Administration
• Strict fluid management     • Antiemetic administration   
• Aggressive side effect managment
• Electrolyte replacement  
      to allow next dose 
• Oxygen titration                              

Rest 7-10 days

Cycle #2 – IL-2 Q 8 hours

RE-STAGE
Rest 8-12 weeks

IL-2 Assessment
Criteria

Hemodynamic

Methods and Interventions

Key Factors for Success

Renal
Weight Gain

Resting SOB
Crackles 1/3 up
chest
3-4 L for sat> 95%
Urine output
<160ml/8 hrs
Creatinine 2.5 – 2.9
15 % over baseline

Yes

No

Absolute Criteria
ST.>130*
EKG Ischemia
Atrial Fibrillation
Bigeminy, V.Tach.
Elevated CPK-MB
Moist Desquamation
Refractory vomiting

Yes

No

Severe abdominal distention
affecting breathing
Unrelenting abdominal pain
Pressors needed for blood
pressure
Frank blood in stools, sputum
Platelets<30,000
Strong clinical suspicion or
documented
Mental status changes
Disorientation, Vivid dreams or
emotional lability
>4L for sat >95%
Crackles ½ up chest
40% O2 mask for sat >95%
Intubation
Urine <80ml/8hr
Creatinine at or > than 3

Hold dose if any relative criteria are checked. Take corrective action and reassess next scheduled time.
D/C therapy 3 or > relative criteria are checked, 1 absolute criteria or dose held x3.

• Private rooms
• Flexible staffing patterns to support 1: 2 nurse/ patient ratio  
• Clinical practice guidelines with nurse driven protocols
• Commitment between nurses, providers and ancillary personnel
to prioritize communication for the IL-2 patient
• Promotion of family presence - at patient’s bedside 24/7 and
participate as partner in care     

Outcomes
Patient Teaching
Information
Lehigh Valley Hospital
John and Dorothy Morgan Cancer Center

ALDESLEUKIN - HIGH DOSE IL-2

POSSIBLE SIDE EFFECTS:
Allergic reactions are rare but signs of reactions are shortness of breath, wheezing, rash, itching,
lightheadedness or palpitations.
Flu like symptoms: fever, headache, chills, muscle and joint aches, along with fatigue.
Decrease in the number of white blood cells, red blood cells and platelets. This will increase your risk
of fatigue, infection and bleeding.
Soreness in the mouth and throat.
Moderate to severe nausea and vomiting.
Diarrhea
Rash on your legs, arms, back or chest.
Itching – dry skin
Decreased appetite
Rectal Bleeding
Effects on the heart
Chest pain
Rapid irregular beat
Heart attack – this is rare
Urine that is dark or foul smelling
Irritability, restlessness or agitation
Hallucinations
Confusion
Trouble sleeping or nightmares
Difficulty concentrating
Fluid build up in your lungs with difficulty Catching your breath
Weight gain – this is temporary
Swelling of the hands and the face
Low blood pressure
Changes in your liver enzymes



WHAT YOU CAN DO:
Do your mouth care after each meal and before going to bed.
Avoid mouth washes with alcohol in them
Stand up slowly and catch your balance before changing position
Let us know if you are feeling confused, having nightmares or having difficulty with mood shifts
Keep your skin moist – use non- steroid lotion may times a day
Let us know if you are having diarrhea, constipation or blood in your stools
Take no medications over or under the counter without letting us know
Stay in bed only to sleep – keep mobile

Patients Treated
• 43 stage-4 melanoma and 23 stage-4 renal cancer patients
Mortality During Treatment
• 0%
• 4 patient transfers to higher level of care
• 8 patients disease-free, equal to NCI national experience
PICC Line Infections
• 0% (n=300)
Average Length of Stay
• 4 days, comparable to the national average
Patient Satisfaction Scores
• Consistently mid-90’s, > peer group and Magnet™ hospital
scores
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